Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics.
Future Med Chem
; 16(15): 1583-1599, 2024 Aug 02.
Article
en En
| MEDLINE
| ID: mdl-38949857
ABSTRACT
PD-L1 is overexpressed on the surface of tumor cells and binds to PD-1, resulting in tumor immune escape. Therapeutic strategies to target the PD-1/PD-L1 pathway involve blocking the binding. Immune checkpoint inhibitors have limited efficacy against tumors because PD-L1 is also present in the cytoplasm. PD-L1 of post-translational modifications (PTMs) have uncovered numerous mechanisms contributing to carcinogenesis and have identified potential therapeutic targets. Therefore, small molecule inhibitors can block crucial carcinogenic signaling pathways, making them a potential therapeutic option. To better develop small molecule inhibitors, we have summarized the PTMs of PD-L1. This review discusses the regulatory mechanisms of small molecule inhibitors in carcinogenesis and explore their potential applications, proposing a novel approach for tumor immunotherapy based on PD-L1 PTM.
[Box see text].
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Procesamiento Proteico-Postraduccional
/
Bibliotecas de Moléculas Pequeñas
/
Antígeno B7-H1
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Future Med Chem
Año:
2024
Tipo del documento:
Article
País de afiliación:
China